Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Protein Kinases: Technologies and Opportunities for Drug Discovery' returned 44 results - Page 1 of 3   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Targeting Kinases for Drug Discovery   Decision Resources, Inc., April 2008, Pages: 28 -30% of all drug discovery programs. Get the Answers You Need to Shape Your Strategy - The protein kinase family is a mostly unexploited class of drug targets. Novartis’s kinase inhibitor Gleevec, approved Strategic Outlook On Protein Kinase Inhibitors in Oncology   Bioseeker, Feb 2006, Pages: 104 in Oncology 6 Protein Kinase Targets – A Growing Family 6.1 Challenges in Protein Kinase Drug Discovery 6.1.1 Enabling Structure-Based Drug Design is the Key 6.1.2 Specific Kinase Inhibitors without Kinase Drug Discovery Technologies - A Global Update of Market Trends & Opportunities   Bizacumen Inc., Nov 2009, Pages: 488 of drug discovery processes and reducing time-to-market. These and other market data and trends are presented in "Drug Discovery Technologies: A Global Update of Market Trends & Opportunities" by Biz The Targeted Cancer Therapies Pipeline: A Strategic Review   Decision Resources, Inc., Dec 2009, Pages: 34 sales. Questions Answered in This Report - The protein kinase superfamily is one of the most important classes of molecules for targeted drug therapy. Which kinase targets have yielded success so far Cancer Drug Resistance   BioPharm Reports (VennBio Ltd.), Jan 2009, Pages: 235 in cancer diagnostics. 3.1 Cancer Stem Cells 3.2 What are Cancer Stem Cells? 3.3 Different Cancers 3.4 Drug Resistance 3.5 Drug Discovery 3.5.1 EGFR/HER2 tyrosine kinase inhibitors 3.5.2 Proposed Innovations in Bioinformatics: Emerging Tools for Drug Discovery and Development   Business Insights, Jan 2008, Pages: 253 the forecast period. - Bioinformatics-enabled protein biomarker discovery will enable the development of safer and more effective drugs, targeted therapies and molecular diagnostics. - Systems biology modelling Synthetic Biology, A New Paradigm For Biological Discovery   Beachhead Consulting, Feb 2006, Pages: 158 at length. Discoveries and applications from the field of synthetic biology, both current and future, are detailed, and business opportunities from these applications are investigated. Biotechnology Personalized Medicine - Scientific and Commercial Aspects   Jain PharmaBiotech, Feb 2012, Pages: 780 Significance of mitochondrial proteome in human disease Proteomic technologies for drug discovery and development Role of reverse-phase protein microarray in drug discovery Role of proteomics in clinical drug Drug Discovery Technologies - Global Strategic Business Report   Global Industry Analysts, Inc., Oct 2008, Pages: 675 This report analyzes the worldwide markets for Drug Discovery Technologies in Millions of US$. The specific technology types analyzed are Bioanalytical Instruments, High Throughput Screening (HTS Nitric Oxide - Therapeutics, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 276 of chemotherapy Factors that enhance availability of NO Modulators of cyclic guanosine-3',5'-monophosphate-dependent protein kinases NOS-modulating drugs Drugs that activate eNOS Statins Angiotensin converting Commercial Opportunities from Biomarkers: Transforming drug discovery, clinical development and molecular diagnostics   Business Insights, May 2006, Pages: 206 via functional genomics What is functional genomics? Target discovery New technologies in functional genomics DNA and protein microarrays New technologies The genomics-derived drug pipeline Case The Complete Guide to Targeted Therapies in Oncology: A World Review   Bioseeker, Dec 2006, Pages: 550 9 Protein Kinase Inhibitors 9.1 Rationale for Development of Kinase Inhibitors in Oncology 9.2 Protein Kinase Targets – A Growing Family 9.3 Challenges in Protein Kinase Drug Discovery 9 Technology Developments in Functional Proteomics (Technical Insights)   Frost & Sullivan, Sep 2006 , restraints, applications, and trends that are impacting the field. In this study, Frost & Sullivan's expert analysts thoroughly examine the following applications: drug discovery, biomarkers, molecular Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline   Bioseeker, June 2010, Pages: 596 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications. The discovery of new cancer therapeutics has seen a significant Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas   Bioseeker, Sep 2007, Pages: 500 care indications - Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer - The included competitive landscape between the five big Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others   Bioseeker, Dec 2011, Pages: 1617 Targets 6.2.31 Phosphoric Diester Hydrolase Activity Targets 6.2.32 Protein Binding Targets 6.2.33 Protein Serine/Threonine Kinase Activity Targets 6.2.34 Protein-tyrosine Kinase Activity Targets A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market   Bioseeker, June 2010, Pages: 838 .2.39 Protein Serine/Threonine Kinase Activity Targets 6.2.40 Protein Serine/Threonine kinase activity Targets 6.2.41 Protein-tyrosine Kinase Activity Targets 6.2.42 Receptor Activity Targets 6.2.43 Receptor Apoptotic Therapeutics in Oncology - Where to Commercialize?   Bioseeker, Nov 2009, Pages: 803 Activity Targets 6.2.30 Protein Binding Targets 6.2.31 Protein Serine/Threonine Kinase Activity Targets 6.2.32 Protein-Tyrosine Kinase Activity Targets 6.2.33 Receptor Activity Targets 6.2.34 Receptor Apoptosis 2009: Opportunities in Cancer and Other Diseases   Biophoenix Limited, Feb 2009, Pages: 312 , at least partly and/or indirectly, via apoptosis modulation. In cancer and in other diseases, elements of the apoptotic process become dysregulated, offering many direct targets for drug discovery What Strategies Will Yield Novel Treatments for Autoimmune Disease?   Decision Resources, Inc., March 2008, Pages: 26 . - Novel approaches to treatment: targeted biologics, new cell technologies, and novel treatment methods are the focus of current drug discovery programs. - Unmet need creates opportunity for new therapies Results:  First -   Prev -   1 -   2 -   3 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network